4.6 Review

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial-Mesenchymal transition

期刊

FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1008027

关键词

platinum-based drugs; epithelial-mesenchymal transition; drug resistance; targeted therapy; cancer stem cells

类别

资金

  1. Beijing Xisike Clinical Oncology Research Foundation
  2. [2020HX037/Y-MSD2020-0354]

向作者/读者索取更多资源

This review discusses the role of platinum-based drugs (PBDs)-induced epithelial-mesenchymal transition (EMT) in cancer drug resistance and emphasizes how this novel knowledge can be exploited to overcome PBD resistance, particularly through EMT-targeted compounds.
Platinum-based drugs (PBDs), including cisplatin, carboplatin, and oxaliplatin, have been widely used in clinical practice as mainstay treatments for various types of cancer. Although there is firm evidence of notable achievements with PBDs in the management of cancers, the acquisition of resistance to these agents is still a major challenge to efforts at cure. The introduction of the epithelial-mesenchymal transition (EMT) concept, a critical process during embryonic morphogenesis and carcinoma progression, has offered a mechanistic explanation for the phenotypic switch of cancer cells upon PBD exposure. Accumulating evidence has suggested that carcinoma cells can enter a resistant state via induction of the EMT. In this review, we discussed the underlying mechanism of PBD-induced EMT and the current understanding of its role in cancer drug resistance, with emphasis on how this novel knowledge can be exploited to overcome PBD resistance via EMT-targeted compounds, especially those under clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据